Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients with Stage IIA-B Prostate Cancer

< Back to search results
This clinical trial matches:
Show Search Criteria
Status: Active

Description

This randomized phase III trial studies how well stereotactic body radiation therapy works compared to intensity-modulated radiation therapy in treating patients with stage IIA-B prostate cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Stereotactic body radiation therapy may work better in treating patients with prostate cancer.

Eligibility Criteria

Inclusion Criteria

  • Previously untreated localized adenocarcinoma of the prostate with the following clinical findings: * Clinical stage by digital rectal exam of either T1c or T2a/b (limited to one side of the gland); (American Joint Committee on Cancer [AJCC], version 7) or cT1a-c or 2a or 2b, stage group IIA or IIB (AJCC, version 8); both versions 7 and 8 staging should be recorded * Patients in active surveillance who elect to be treated are eligible if they meet protocol requirements * Stages T1a-T1b are eligible if patient underwent transurethral prostatic resection (TURP) previously Gleason score must be Gleason 7(3+4) with a PSA < 20 ng/mL, or Gleason 6(3+3) with a PSA > 10 ng/mL and < 20 ng/mL; (AJCC, version 7) or group grade 1 or 2, stage Group IIA or IIB (AJCC version 8) ** If patient is receiving a 5-alpha reductase inhibitor at the time of enrollment the baseline PSA value will be assumed to be double the initial value and the medication should be discontinued but does not need to have a washout period to participate, to remain eligible a PSA drawn while still on the medicine must be: *** < 10 ng/mL to remain eligible if Gleason 7(3+4) **** Stratification level 1 if PSA < 5 ng/mL and level 2 if less than 10 ng/mL *** > 5 ng/mL and less than 10 ng/mL for Gleason 6(3+3) **** Stratification level 3 * Percent of submitted positive core biopsies must be < 50% of all sextants ** NOTE: all cores from a targeted lesion will be counted as an N of 1 core for calculating percent positive cores in total * The prostate volume must be < 60 cc as reported at time of biopsy or by separate measure with ultrasound or other imaging modalities including magnetic resonance imaging (MRI) or computed tomography (CT) scan
  • History and physical including a digital rectal exam 60 days prior to registration
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1 60 days prior to registration
  • MRI of pelvis within 90 days prior to registration
  • Bone scan as clinically indicated within 90 days prior to registration
  • Charlson modified co-morbidity score =< 3 for patients under 60 and =< 4 for patients 60 and over 21 days prior to registration
  • International prostate symptom score (IPSS) of < 15 21 days prior to registration
  • The patient must provide study-specific informed consent prior to study entry
  • Willingness and ability to complete the Expanded Prostate Cancer Index Composite (EPIC-26) questionnaire
  • Completion of all items of the EPIC-26 which will be data entered at registration 60 days prior to registration
  • Only English, Spanish, and French-speaking patients are eligible to participate

Exclusion Criteria

  • Definitive clinical or radiologic evidence of metastatic disease; no nodal involvement or evidence of metastatic disease allowed as defined by screening of the pelvis
  • Definitive T3 disease on MRI
  • Prior or current invasive malignancy with current evidence of active disease within the past 3 years
  • Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable; must be off treatment for at least 3 years; (applicable only to studies that incorporate systemic therapy)
  • Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
  • The use of hormonal therapy is not allowed; if the patient in on a 5-alpha reductase inhibitor, then they should be stopped prior to treatment once enrolled onto the study; no washout period is required for this study to participate
  • Severe, active co-morbidity defined as follows: * Human immunodeficiency virus (HIV) positive with CD4 count < 200 cells/microliter; Note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; Note also that HIV testing is not required for eligibility for this protocol * Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol; (patients on Coumadin or other blood thinning agents are eligible for this study)
  • Contraindication to MRI * Cardiac pacemaker or defibrillator * Surgically implanted electrical devices such as spinal stimulation devices or intracranial stimulation devices, cochlear implants, the presence of metallic foreign bodies in the orbits, and incompatible old mechanical heart valves and aneurysm clips

Locations & Contacts

Alabama

Tuscaloosa
Lewis and Faye Manderson Cancer Center
Status: Active
Contact: Site Public Contact
Phone: 800-338-2948

Arizona

Gilbert
Arizona Breast Cancer Specialists-Gilbert
Status: Active
Contact: Site Public Contact
Phone: 480-922-4600
Peoria
Arizona Center for Cancer Care-Peoria
Status: Active
Contact: Site Public Contact
Phone: 623-773-2873
Scottsdale
Arizona Breast Cancer Specialists-Scottsdale
Status: Active
Contact: Site Public Contact
Phone: 480-922-4600
Surprise
Arizona Center for Cancer Care-Surprise
Status: Active
Contact: Site Public Contact
Phone: 412-339-5294 Email: Roster@nrgoncology.org
Tucson
Arizona Oncology Associates-West Orange Grove
Status: Active
Contact: Site Public Contact
Phone: 520-544-2919

Arkansas

Little Rock
University of Arkansas for Medical Sciences
Status: Active
Contact: Site Public Contact
Phone: 501-686-8274

California

Berkeley
Alta Bates Summit Medical Center-Herrick Campus
Status: Active
Contact: Site Public Contact
Phone: 415-209-2686 Email: bernicl@sutterhealth.org
Greenbrae
Marin General Hospital
Status: Active
Contact: Site Public Contact
Phone: 415-925-7325
La Jolla
UC San Diego Moores Cancer Center
Status: Active
Contact: Site Public Contact
Phone: 858-822-5354 Email: cancercto@ucsd.edu
Los Angeles
Los Angeles County-USC Medical Center
Status: Active
Contact: Site Public Contact
Phone: 323-865-0451
USC / Norris Comprehensive Cancer Center
Status: Active
Contact: Site Public Contact
Phone: 323-865-0451
Rancho Cordova
Kaiser Permanente-Rancho Cordova Cancer Center
Status: Active
Contact: Site Public Contact
Phone: 877-642-4691 Email: Kpoct@kp.org
Roseville
The Permanente Medical Group-Roseville Radiation Oncology
Status: Active
Contact: Site Public Contact
Phone: 877-642-4691 Email: Kpoct@kp.org
Sacramento
University of California Davis Comprehensive Cancer Center
Status: Active
Contact: Site Public Contact
Phone: 916-734-3089
Santa Clara
Kaiser Permanente Medical Center - Santa Clara
Status: Active
Contact: Site Public Contact
Phone: 877-642-4691 Email: Kpoct@kp.org
South San Francisco
Kaiser Permanente Cancer Treatment Center
Status: Active
Contact: Site Public Contact
Phone: 877-642-4691 Email: Kpoct@kp.org
Truckee
Gene Upshaw Memorial Tahoe Forest Cancer Center
Status: Active
Contact: Site Public Contact
Phone: 530-582-6450

Colorado

Aurora
University of Colorado Hospital
Status: Active
Contact: Site Public Contact
Phone: 720-848-0650
Colorado Springs
Memorial Hospital North
Status: Active
Contact: Site Public Contact
Phone: 719-364-6700
UCHealth Memorial Hospital Central
Status: Active
Contact: Site Public Contact
Phone: 719-365-2406
Fort Collins
Poudre Valley Hospital
Status: Active
Contact: Site Public Contact
Phone: 970-297-6150

Connecticut

New Haven
Yale University
Status: Active
Contact: Site Public Contact
Phone: 203-785-5702 Email: canceranswers@yale.edu

Delaware

Newark
Christiana Care Health System-Christiana Hospital
Status: Active
Contact: Site Public Contact
Phone: 302-623-4450 Email: KDempsey@christianacare.org
Helen F Graham Cancer Center
Status: Active
Contact: Site Public Contact
Phone: 302-623-4450 Email: KDempsey@christianacare.org

Georgia

Atlanta
Emory Saint Joseph's Hospital
Status: Active
Contact: Site Public Contact
Phone: 412-339-5294 Email: Roster@nrgoncology.org
Emory University Hospital / Winship Cancer Institute
Status: Active
Contact: Site Public Contact
Phone: 404-778-1868
Emory University Hospital Midtown
Status: Active
Contact: Site Public Contact
Phone: 888-946-7447
Grady Health System
Status: Active
Contact: Site Public Contact
Phone: 404-489-9164
Piedmont Hospital
Status: Active
Contact: Site Public Contact
Phone: 404-425-7943 Email: ORS@piedmont.org
Savannah
Lewis Cancer and Research Pavilion at Saint Joseph's / Candler
Status: Active
Contact: Site Public Contact
Phone: 412-339-5294 Email: Roster@nrgoncology.org

Illinois

Decatur
Decatur Memorial Hospital
Status: Active
Contact: Site Public Contact
Phone: 217-876-4740 Email: rhamrick@dmhhs.org
Effingham
Crossroads Cancer Center
Status: Active
Contact: Site Public Contact
Phone: 217-876-4740 Email: rhamrick@dmhhs.org
Maywood
Loyola University Medical Center
Status: Active
Contact: Site Public Contact
Phone: 708-226-4357
Peoria
OSF Saint Francis Medical Center
Status: Active
Contact: Site Public Contact
Phone: 309-243-3605 Email: andersonj@illinoiscancercare.com
Urbana
Carle Cancer Center
Status: Active
Contact: Site Public Contact
Phone: 800-446-5532 Email: Research@carle.com

Indiana

Fort Wayne
Parkview Hospital Randallia
Status: Active
Contact: Site Public Contact
Phone: 260-373-8888 Email: parkviewresearch@parkview.com

Kansas

Kansas City
University of Kansas Cancer Center
Status: Active
Contact: Site Public Contact
Phone: 913-945-7552 Email: ctnursenav@kumc.edu
Overland Park
University of Kansas Cancer Center-Overland Park
Status: Active
Contact: Site Public Contact
Phone: 913-945-7552 Email: ctnursenav@kumc.edu
Wichita
Via Christi Regional Medical Center
Status: Active
Contact: Site Public Contact
Phone: 800-362-0070 Email: Keisha.humphries@ascension.org

Louisiana

Metairie
East Jefferson General Hospital
Status: Active
Contact: Site Public Contact
Phone: 504-210-3539 Email: trials@jeffradonc.com

Maine

Portland
Maine Medical Center-Bramhall Campus
Status: Active
Contact: Site Public Contact
Phone: 207-885-7565
Scarborough
Maine Medical Center- Scarborough Campus
Status: Active
Contact: Site Public Contact
Phone: 207-396-8090 Email: wrighd@mmc.org

Maryland

Baltimore
Saint Agnes Hospital
Status: Active
Contact: Site Public Contact
Phone: 410-368-2910
Salisbury
Peninsula Regional Medical Center
Status: Active
Contact: Site Public Contact
Phone: 866-922-6237

Massachusetts

Boston
Boston Medical Center
Status: Active
Contact: Site Public Contact
Phone: 617-638-8265

Michigan

Ann Arbor
University of Michigan Comprehensive Cancer Center
Status: Active
Contact: Site Public Contact
Phone: 800-865-1125
Clarkston
21st Century Oncology MHP - Clarkston
Status: Active
Contact: Site Public Contact
Phone: 248-338-0663
Farmington Hills
21st Century Oncology MHP - Farmington
Status: Active
Contact: Site Public Contact
Phone: 248-338-0663
Grand Rapids
Spectrum Health at Butterworth Campus
Status: Active
Contact: Site Public Contact
Phone: 616-391-1230 Email: crcwm-regulatory@crcwm.org
Troy
21st Century Oncology MHP - Troy
Status: Active
Contact: Site Public Contact
Phone: 248-338-0663

Minnesota

Bemidji
Sanford Clinic North-Bemidgi
Status: Active
Contact: Site Public Contact
Phone: 218-333-5000
Saint Paul
Regions Hospital
Status: Active
Contact: Site Public Contact
Phone: 952-993-1517 Email: mmcorc@healthpartners.com

Missouri

Cape Girardeau
Southeast Cancer Center
Status: Active
Contact: Site Public Contact
Phone: 573-651-5550
Saint Louis
Missouri Baptist Medical Center
Status: Active
Contact: Site Public Contact
Phone: 314-996-5569
Siteman Cancer Center-South County
Status: Active
Contact: Site Public Contact
Phone: 800-600-3606 Email: info@siteman.wustl.edu
Washington University School of Medicine
Status: Active
Contact: Site Public Contact
Phone: 800-600-3606 Email: info@siteman.wustl.edu
Saint Peters
Siteman Cancer Center at Saint Peters Hospital
Status: Active
Contact: Site Public Contact
Phone: 800-600-3606 Email: info@siteman.wustl.edu

Montana

Great Falls
Benefis Healthcare- Sletten Cancer Institute
Status: Active
Contact: Site Public Contact
Phone: 406-969-6060 Email: mccinfo@mtcancer.org
Kalispell
Kalispell Regional Medical Center
Status: Active
Contact: Site Public Contact
Phone: 406-969-6060 Email: mccinfo@mtcancer.org

New Hampshire

Lebanon
Dartmouth Hitchcock Medical Center
Status: Active
Contact: Site Public Contact
Phone: 800-639-6918 Email: cancer.research.nurse@dartmouth.edu

New Mexico

Albuquerque
Lovelace Radiation Oncology
Status: Temporarily closed to accrual
Contact: Site Public Contact
Phone: 505-272-0530 Email: AYost@nmcca.org
New Mexico Oncology Hematology Consultants
Status: Active
Contact: Site Public Contact
Phone: 505-272-0530 Email: CLee@nmcca.org
University of New Mexico Cancer Center
Status: Active
Contact: Site Public Contact
Phone: 505-925-0366 Email: LByatt@nmcca.org

North Carolina

Supply
NHRMC Radiation Oncology - Supply
Status: Active
Contact: Site Public Contact
Phone: 910-754-4716
Wilmington
NHRMC Radiation Oncology - 16th Street
Status: Active
Contact: Site Public Contact
Phone: 910-251-1839

North Dakota

Bismarck
Sanford Bismarck Medical Center
Status: Active
Contact: Site Public Contact
Phone: 701-323-5760 Email: tamara.fischer@sanfordhealth.org
Fargo
Roger Maris Cancer Center
Status: Active
Contact: Site Public Contact
Phone: 701-234-6161

Ohio

Akron
Cleveland Clinic Akron General
Status: Active
Contact: Site Public Contact
Phone: 866-223-8100 Email: CancerAnswer@ccf.org
Beachwood
UHHS-Chagrin Highlands Medical Center
Status: Active
Contact: Site Public Contact
Phone: 800-641-2422 Email: CTUReferral@UHhospitals.org
Chardon
Geauga Hospital
Status: Active
Contact: Site Public Contact
Phone: 800-641-2422 Email: CTUReferral@UHhospitals.org
Cleveland
Case Western Reserve University
Status: Active
Contact: Site Public Contact
Phone: 800-641-2422 Email: CTUReferral@UHhospitals.org
Cleveland Clinic Cancer Center / Fairview Hospital
Status: Active
Contact: Site Public Contact
Phone: 866-223-8100 Email: CancerAnswer@ccf.org
Columbus
Ohio State University Comprehensive Cancer Center
Status: Active
Contact: Site Public Contact
Phone: 800-293-5066 Email: Jamesline@osumc.edu
Elyria
Mercy Cancer Center-Elyria
Status: Active
Contact: Site Public Contact
Phone: 800-641-2422 Email: CTUReferral@UHhospitals.org
Mansfield
Cleveland Clinic Cancer Center Mansfield
Status: Active
Contact: Site Public Contact
Phone: 866-223-8100 Email: CancerAnswer@ccf.org
Mayfield Heights
Hillcrest Hospital Cancer Center
Status: Active
Contact: Site Public Contact
Phone: 866-223-8100 Email: CancerAnswer@ccf.org
Mentor
Lake University Ireland Cancer Center
Status: Active
Contact: Site Public Contact
Phone: 800-641-2422 Email: CTUReferral@UHhospitals.org
Sandusky
North Coast Cancer Care
Status: Active
Contact: Site Public Contact
Phone: 866-223-8100 Email: CancerAnswer@ccf.org
Westlake
UHHS-Westlake Medical Center
Status: Active
Contact: Site Public Contact
Phone: 800-641-2422 Email: CTUReferral@UHhospitals.org
Wooster
Cleveland Clinic Wooster Family Health and Surgery Center
Status: Active
Contact: Site Public Contact
Phone: 866-223-8100 Email: CancerAnswer@ccf.org

Oklahoma

Oklahoma City
University of Oklahoma Health Sciences Center
Status: Active
Contact: Site Public Contact
Phone: 405-271-8777 Email: ou-clinical-trials@ouhsc.edu

Pennsylvania

Chadds Ford
Christiana Care Health System-Concord Health Center
Status: Active
Contact: Site Public Contact
Phone: 302-623-4450 Email: KDempsey@christianacare.org
Danville
Geisinger Medical Center
Status: Active
Contact: Site Public Contact
Phone: 570-271-5251 Email: HemonCCTrials@geisinger.edu
Drexel Hill
Delaware County Memorial Hospital
Status: Active
Contact: Site Public Contact
Phone: 610-284-8237 Email: jolene.garney@crozer.org
Paoli
Paoli Memorial Hospital
Status: Active
Contact: Site Public Contact
Phone: 484-476-2649 Email: turzoe@mlhs.org
Philadelphia
Thomas Jefferson University Hospital
Status: Active
Contact: Site Public Contact
Phone: 215-955-6084
West Reading
Reading Hospital
Status: Active
Contact: Site Public Contact
Phone: 610-988-9323
Wilkes-Barre
Geisinger Wyoming Valley / Henry Cancer Center
Status: Active
Contact: Site Public Contact
Phone: 570-271-5251 Email: HemonCCTrials@geisinger.edu
Wynnewood
Lankenau Medical Center
Status: Active
Contact: Site Public Contact
Phone: 484-476-2649 Email: turzoe@mlhs.org

South Carolina

Charleston
Medical University of South Carolina
Status: Active
Contact: Site Public Contact
Phone: 843-792-9321 Email: hcc-clinical-trials@musc.edu
Greenville
Greenville Health System Cancer Institute-Eastside
Status: Active
Contact: Site Public Contact
Phone: 864-241-6251 Email: kwilliams8@ghs.org
Greenville Health System Cancer Institute-Faris
Status: Active
Contact: Site Public Contact
Phone: 864-241-6251 Email: kwilliams8@ghs.org
Greenwood
Self Regional Healthcare
Status: Active
Contact: Site Public Contact
Phone: 864-725-4771 Email: nmcgaha@selfregional.org
Hilton Head Island
The Radiation Oncology Center-Hilton Head / Bluffton
Status: Active
Contact: Site Public Contact
Phone: 912-819-5704 Email: underberga@sjchs.org
Seneca
Greenville Health System Cancer Institute-Seneca
Status: Active
Contact: Site Public Contact
Phone: 864-241-6251 Email: kwilliams8@ghs.org
Spartanburg
Greenville Health System Cancer Institute-Spartanburg
Status: Active
Contact: Site Public Contact
Phone: 864-241-6251 Email: kwilliams8@ghs.org

South Dakota

Sioux Falls
Sanford USD Medical Center - Sioux Falls
Status: Active
Contact: Site Public Contact
Phone: 605-312-3320 Email: OncologyClinicalTrialsSF@SanfordHealth.org

Texas

Abilene
Texas Cancer Center
Status: Active
Contact: Site Public Contact
Phone: 412-339-5294 Email: Roster@nrgoncology.org
McKinney
Texas Oncology-McKinney
Status: Active
Contact: Site Public Contact
Phone: 972-542-8609
Plano
Texas Oncology-Plano West
Status: Active
Contact: Site Public Contact
Phone: 412-339-5294 Email: Roster@nrgoncology.org
Webster
Deke Slayton Cancer Center
Status: Active
Contact: Site Public Contact
Phone: 412-339-5294 Email: Roster@nrgoncology.org

Utah

Murray
Intermountain Medical Center
Status: Active
Contact: Site Public Contact
Phone: 801-507-3950 Email: officeofresearch@imail.org
Provo
Utah Valley Regional Medical Center
Status: Active
Contact: Site Public Contact
Phone: 801-357-7965 Email: officeofresearch@imail.org

Vermont

Burlington
University of Vermont Medical Center
Status: Active
Contact: Site Public Contact
Phone: 802-656-4101
Saint Johnsbury
Norris Cotton Cancer Center-North
Status: Active
Contact: Site Public Contact
Phone: 802-473-4100

Wisconsin

Brookfield
Wheaton Franciscan Healthcare-Elmbrook Memorial Hospital
Status: Active
Contact: Site Public Contact
Phone: 262-785-2273
Franklin
Wheaton Franciscan Healthcare-Saint Francis / Reiman Cancer Center
Status: Active
Contact: Site Public Contact
Phone: 262-785-2273
Green Bay
Aurora BayCare Medical Center
Status: Active
Contact: Site Public Contact
Phone: 414-302-2304 Email: ncorp@aurora.org
Menomonee Falls
Community Memorial Hospital
Status: Active
Contact: Site Public Contact
Phone: 262-257-5100
Milwaukee
Aurora Saint Luke's Medical Center
Status: Active
Contact: Site Public Contact
Phone: 412-339-5294 Email: Roster@nrgoncology.org
Froedtert and the Medical College of Wisconsin
Status: Active
Contact: Site Public Contact
Phone: 414-805-4380
Racine
Wheaton Franciscan Cancer Care - All Saints
Status: Active
Contact: Site Public Contact
Phone: 262-785-2273
West Bend
The Alyce and Elmore Kraemer Cancer Care Center
Status: Active
Contact: Site Public Contact
Phone: 866-680-0505

Alberta

Calgary
Tom Baker Cancer Centre
Status: Active
Contact: Site Public Contact
Phone: 403-521-3433

Ontario

Ottawa
Ottawa Hospital and Cancer Center-General Campus
Status: Active
Contact: Site Public Contact
Phone: 613-761-4395

Quebec

Montreal
CHUM - Centre Hospitalier de l'Universite de Montreal
Status: Active
Contact: Site Public Contact
Phone: 412-339-5294 Email: Roster@nrgoncology.org
The Research Institute of the McGill University Health Centre (MUHC)
Status: Active
Contact: Site Public Contact
Phone: 514-934-1934ext48354 Email: evelyn.ortega@muhc.mcgill.ca

Saskatchewan

Saskatoon
Saskatoon Cancer Centre
Status: Active
Contact: Site Public Contact
Phone: 306-655-2914

Trial Objectives and Outline

PRIMARY OBJECTIVES:

I. To determine whether stereotactic body radiation therapy (SBRT) can be shown to be superior to hypofractionated intensity-modulated radiation therapy (IMRT) in terms of genitourinary (GU) and gastrointestinal (GI) toxicity by having fewer patients that experience a minimal important decline (MID) in urinary irritation/obstructive and bowel Health Related Quality of Life (HRQOL) as measured by Expanded Prostate Cancer Index Composite (EPIC)-26 at 24 months post completion of therapy.

II. To determine if SBRT (5 fractions of 7.25 Gy) is superior to hypofractionated IMRT (28 fractions of 2.5 Gy) as measured by disease free survival (DFS).

SECONDARY OBJECTIVES:

I. To determine whether SBRT can be shown to be superior to hypofractionated IMRT at 12 and 24 months post completion of therapy in terms of HRQOL by having fewer patients that experience a minimal important decline (MID) bowel (12 months only) sexual, hormonal, urinary irritation/obstructive (12 months only) and in urinary incontinence HRQOL as measured by EPIC-26.

II. To determine if SBRT (5 fractions of 7.25 Gy) is superior to hypofractionated IMRT (28 fractions of 2.5 Gy) as measured by biochemical failure, overall survival, local failure, prostate cancer specific survival, and distant metastases.

III. To determine the correspondence between the diagnostic magnetic resonance imaging (MRI) and biopsy.

TERTIARY OBJECTIVES:

I. To determine whether a potentially more expensive therapy, SBRT, would be cost-effective than standard hypofractionated IMRT as measured by the European Quality of Life Five Dimension Five Level Scale Questionnaire (EQ-5D-5L).

II. To explore the relationship between prostate imaging-reporting and data system (PIRADS)version (v)2 grade with biochemical failure.

III. Collect specimens for future translational research analyses.

OUTLINE: Patients are randomized into 1 of 2 arms.

ARM I: Patients undergo IMRT once daily for 5 fractions per week for 28 fractions over less than 32 business days.

ARM II: Patients undergo SBRT at least every other day for 2-3 fractions per week for 5 fractions over less than 12 business days.

After completion of study treatment, patients are followed up every 6-12 months for 2 years.

Trial Phase & Type

Trial Phase

Phase III

Trial Type

Treatment

Lead Organization

Lead Organization
NRG Oncology

Principal Investigator
Rodney J. Ellis

Trial IDs

Primary ID NRG-GU005
Secondary IDs NCI-2017-01398
Clinicaltrials.gov ID NCT03367702